12-48119238-G-C
Position:
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 0P and 7B. BP4_ModerateBS1_SupportingBS2
The NM_001354740.1(PFKM):c.-89G>C variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000334 in 981,918 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.0015 ( 3 hom., cov: 32)
Exomes 𝑓: 0.00011 ( 0 hom. )
Consequence
PFKM
NM_001354740.1 5_prime_UTR
NM_001354740.1 5_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 3.50
Genes affected
PFKM (HGNC:8877): (phosphofructokinase, muscle) Three phosphofructokinase isozymes exist in humans: muscle, liver and platelet. These isozymes function as subunits of the mammalian tetramer phosphofructokinase, which catalyzes the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate. Tetramer composition varies depending on tissue type. This gene encodes the muscle-type isozyme. Mutations in this gene have been associated with glycogen storage disease type VII, also known as Tarui disease. Alternatively spliced transcript variants have been described.[provided by RefSeq, Nov 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -7 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.34).
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00155 (236/152266) while in subpopulation AFR AF= 0.00537 (223/41554). AF 95% confidence interval is 0.00479. There are 3 homozygotes in gnomad4. There are 126 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAd4 at 3 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PFKM | NM_001354740.1 | c.-89G>C | 5_prime_UTR_variant | 1/23 | NP_001341669.1 | |||
PFKM | XM_047429003.1 | c.-89G>C | 5_prime_UTR_variant | 1/22 | XP_047284959.1 | |||
PFKM | NM_001354735.1 | c.301+661G>C | intron_variant | NP_001341664.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PFKM | ENST00000642730.1 | c.301+661G>C | intron_variant | ENSP00000496597.1 | ||||||
PFKM | ENST00000550257.7 | c.215-3529G>C | intron_variant | 4 | ENSP00000447997.3 | |||||
PFKM | ENST00000340802.12 | c.206-3529G>C | intron_variant | 2 | ENSP00000345771.6 |
Frequencies
GnomAD3 genomes AF: 0.00154 AC: 234AN: 152148Hom.: 3 Cov.: 32
GnomAD3 genomes
AF:
AC:
234
AN:
152148
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.000111 AC: 92AN: 829652Hom.: 0 Cov.: 19 AF XY: 0.000120 AC XY: 46AN XY: 383322
GnomAD4 exome
AF:
AC:
92
AN:
829652
Hom.:
Cov.:
19
AF XY:
AC XY:
46
AN XY:
383322
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00155 AC: 236AN: 152266Hom.: 3 Cov.: 32 AF XY: 0.00169 AC XY: 126AN XY: 74444
GnomAD4 genome
AF:
AC:
236
AN:
152266
Hom.:
Cov.:
32
AF XY:
AC XY:
126
AN XY:
74444
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Glycogen storage disease, type VII Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Dec 21, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at